Announcement

Collapse
No announcement yet.

Ocrevus Reduces MS Relapse Risk, But Linked to More Hospitalizations

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Ocrevus Reduces MS Relapse Risk, But Linked to More Hospitalizations

    Ocrevus (ocrelizumab) reduces relapse risk and slows disability progression in multiple sclerosis (MS) but also is associated with higher hospitalization rates in older people with relapsing forms of the disease, a new observational study reports.

    Hospitalizations — which occurred mainly due to urinary tract infections — were more frequent in adults ages 55 and older than in those below that age, the study found.

    “Although patients older than 55 were not at higher risk of having an infection, the number of hospitalisations in older patients in our [study] due to an infection is concerning,” the researchers wrote.

    “Given these … observations, we recommend that the patient’s age and level of disability should be taken into account when considering the use of ocrelizumab [Ocrevus] and should prompt very close monitoring when it is employed in older and more disabled patients,” they wrote.

    Full article:

    Ocrevus Reduces MS Relapse Risk, But Linked to More Hospitalizations (multiplesclerosisnewstoday.com)
    PPMS for 23 years (dx 1998)
    ~ Worrying will not take away tomorrow's troubles ~ But it will take away today's peace. ~
Working...
X